Ribonexus, a biotechnology start-up developing new therapies that can overcome resistance to current targeted therapies in cancer patients, has received €2 million ($2.19m) in funds from the French public investment bank Bpifrance.
This financing, which has been granted in connection with the French government’s ‘Deeptech Plan’, will enable Ribonexus to select the best drug candidate to enter preclinical development and leverage its proprietary platform based on a key selective pathway.
The company will receive two instalments via the French government’s ‘Future Investments Program’: €1.4m ($1.53m) in the form of a repayable advance and €600k ($658k) in grants.